Recordati Rare Diseases North America
Dr. Ignacio Alvarez has extensive experience in the pharmaceutical industry. Ignacio currently holds the position of Head of Clinical Development Oncology at Recordati Rare Diseases Inc. starting in September 2022. Prior to this role, they served as the Global Medical Director at EUSA Pharma from December 2020.
Before joining EUSA Pharma, Dr. Alvarez worked at BioMarin Pharmaceutical Inc., where they held various positions including Senior Medical Director, Senior Medical Director of Global Medical Affairs, Director of Global Medical Affairs, and Director of Medical Affairs EUMEA from 2016 to 2019.
Dr. Alvarez also gained experience at Alexion Pharmaceuticals as the Medical Director of Metabolic Diseases from 2013 to 2016 and at Merck Serono as a Senior Medical Manager from 2007 to 2012.
Their earlier career included serving as a Medical Director at Rottapharm from 2004 to 2007 and as a Medical Manager/Medical Advisor at Schering España from 2003 to 2006.
Dr. Ignacio Alvarez pursued their education in Medicine and Surgery at the Universidad Complutense de Madrid, from 1986 to 1994. Here, they earned their Doctor of Medicine (MD) degree.
This person is not in any offices
Recordati Rare Diseases North America
1 followers
Recordati Rare Diseases Inc. (RRD) markets products to treat rare diseases. RRD is a member of the Recordati Group, which includes Recordati S.p.A., Orphan Europe, among other companies around the globe. The Recordati Group, which was established in 1926 currently employs more than 4,000 worldwide. The RRD mission is to reduce the impact of extremely rare and devastating diseases by providing urgently needed therapies. We work side-by-side with rare disease communities to increase awareness, improve diagnosis and expand availability of treatments for people with rare diseases.